STO · NANEXA.ST
Nanexa AB (publ)
SEK 10.32+SEK 0.14 (+1.38%)
Nanexa AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 33.42% below the high.
Loading market information…
STO · XINT.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 02:38 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Xintela AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 67.32% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Xintela AB (publ)’s next earnings report is currently expected on Nov 27, 2026, with estimated earnings per share of -SEK 0.04. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Xintela AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Xintela AB (publ), a biomedical company established in 2009 in Lund, Sweden, concentrates its efforts on two key areas: regenerative medicine, particularly for cartilage repair, and oncology, with a focus on brain tumors. Central to their work is XINMARK, a patented marker technology used to accurately identify and isolate specific stem cells that can develop into cartilage cells. Their product portfolio includes XSTEM, a stem cell-based therapy undergoing clinical trials for treating knee osteoarthritis and persistent leg ulcers. They also offer EQSTEM, another stem cell product, for managing joint conditions in horses. In oncology, Xintela is engaged in the preclinical development of therapeutic antibodies designed to combat aggressive cancers like glioblastoma, a severe brain tumor, and triple-negative breast cancer.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:42 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 23, 2025 |
| -SEK 0.010.0% vs estimate |
| SEK 140.00K |
| Q4 2024 | Feb 28, 2025 | -SEK 0.02 | SEK 1.09M |
|---|
| Q3 2024 | Nov 22, 2024 | -SEK 0.01 | SEK 2.82M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 10.32+SEK 0.14 (+1.38%)
Nanexa AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 33.42% below the high.
SEK 5.17-SEK 0.17 (-3.18%)
Mendus AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 39.1% below the high.
SEK 3.17+SEK 0.12 (+3.93%)
Bio-Works Technologies AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 36.35% below the high.
SEK 2.12+SEK 0.07 (+3.41%)
IRLAB Therapeutics AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 23.74% below the high.
SEK 14.35+SEK 0.10 (+0.7%)
Lipum AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 28.07% below the high.
SEK 0.78-SEK 0.00 (-0.64%)
Intervacc AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 46.65% below the high.
SEK 0.18-SEK 0.00 (-1.85%)
Acarix AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 47.69% below the high.
SEK 2.74-SEK 0.11 (-3.69%)
Elicera Therapeutics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 60.86% below the high.
